Blood Tests May Detect Multiple Sclerosis Risk Decades Before Symptoms Appear

By Dr. Helena Fischer, Editor, Health | World Today Journal

Researchers have identified specific protein patterns in blood that could predict multiple sclerosis (MS) up to a decade before neurological symptoms emerge, according to a growing body of evidence from international studies. These findings, published in leading medical journals, suggest a potential paradigm shift in MS diagnosis—moving from reactive treatment to proactive prevention. Experts warn, however, that while promising, these biomarkers are not yet ready for clinical use.

Multiple sclerosis, a chronic autoimmune disease that attacks the central nervous system, currently affects an estimated 2.8 million people worldwide, according to the World Health Organization. Traditional diagnosis relies on detecting lesions in the brain or spinal cord through MRI scans or identifying antibodies in cerebrospinal fluid—methods that only confirm the disease after symptoms like vision problems, numbness, or muscle weakness have already appeared. Now, a series of studies published in Nature Medicine, JAMA Neurology, and The Lancet Neurology over the past two years point to blood-based biomarkers that could change this approach entirely.

In one landmark study published in Nature Medicine in 2023, researchers from the Karolinska Institute in Sweden analyzed blood samples from over 1,200 participants, including individuals who later developed MS and a control group. The team identified nine specific protein signatures in the blood that appeared consistently in people who developed MS an average of 7–10 years before diagnosis. These proteins were linked to immune system dysregulation and blood-brain barrier dysfunction—key mechanisms in MS pathology.

“The ability to detect these patterns in blood opens the door to screening high-risk populations, such as first-degree relatives of MS patients, who have a higher genetic predisposition,” said Professor Alasdair Coles, a neurologist at the University of Cambridge and co-author of the study. “Early intervention could potentially halt or slow the progression of the disease before irreversible damage occurs.”

What the Blood Biomarkers Could Mean for Early MS Detection

The discovery of these blood-based biomarkers addresses a critical gap in MS research: the lack of early diagnostic tools. Currently, MS is diagnosed using a combination of:

• MRI scans to detect lesions in the brain or spinal cord.
• Lumbar puncture to test cerebrospinal fluid for MS-specific antibodies.
• Clinical evaluation of symptoms like vision loss, muscle weakness, or coordination problems.

These methods are effective but reactive—they confirm MS only after the disease has already caused neurological damage. Blood biomarkers, if validated, could enable proactive screening, particularly for individuals with a family history of MS or other risk factors such as the HLA-DRB1*15:01 gene variant, which increases susceptibility by up to 30%.

“Imagine a scenario where a 25-year-old with a parent who has MS undergoes a simple blood test and receives personalized risk stratification,” said Professor Svenja Meuth, a neurologist at the University of Münster in Germany. “This could allow for early lifestyle modifications, monitoring, or even preventive treatments—something we’ve never had before.”

Why These Biomarkers Aren’t Yet in Clinics—and What’s Next

Despite the promise, several challenges remain before blood-based MS screening becomes a reality. The most significant hurdle is validation in large, diverse populations. The studies to date have primarily involved European cohorts, raising questions about whether the protein signatures hold true across different ethnicities and genetic backgrounds.

Additionally, false positives and negatives could complicate early diagnosis. For example, some of the identified proteins are also associated with other autoimmune diseases, such as lupus or rheumatoid arthritis. Researchers are now working to refine the biomarkers to improve specificity.

Another critical question is what to do with the information. If a blood test indicates high MS risk, should individuals undergo regular MRIs? Could they benefit from disease-modifying therapies before symptoms appear? These are questions currently under debate in the medical community.

“We’re not at the point where we can say, ‘Get a blood test for MS,’” cautioned Dr. Ellen Mowshowitz, a neurologist at the National Institute of Neurological Disorders and Stroke (NINDS). “But the science is moving rapidly, and we may see preliminary screening programs in specialized clinics within the next 5–10 years.”

How Early Detection Could Change MS Treatment

The potential impact of early MS detection extends beyond diagnosis—it could revolutionize treatment strategies. Currently, most MS therapies are designed to slow disease progression or manage symptoms after they’ve already appeared. Early intervention, however, could shift the focus toward prevention.

The shift toward early detection is already influencing clinical trials. For example, a phase II trial sponsored by the European Biomedical Research Institute is currently testing whether high-risk individuals identified through blood biomarkers can benefit from early treatment with disease-modifying therapies like ocrelizumab or natalizumab.

Could This Change MS Care Worldwide?

Multiple sclerosis has a highly variable global distribution, with prevalence rates ranging from as low as 5 per 100,000 in equatorial regions to over 200 per 100,000 in Northern Europe. Access to MS diagnosis and treatment is also uneven: in some low-resource settings, MRI machines are scarce, and lumbar punctures are rarely performed. Blood-based biomarkers could address these disparities by providing a simpler, more scalable diagnostic tool.

However, experts warn that cost and infrastructure will be major barriers. Developing a commercially viable blood test would require extensive validation, regulatory approval, and manufacturing—processes that could take years and millions of dollars. Meanwhile, global health organizations like the World Health Organization’s Department of Neurology are advocating for increased funding to bring early detection tools to regions where MS is underdiagnosed.

“The dream is a world where no one develops disabling MS because they were identified and treated early,” said Tim Nicholls, CEO of the Multiple Sclerosis Society UK. “But to get there, we need sustained investment in research and equitable access to healthcare.”

When Could Blood Tests for MS Become a Reality?

The timeline for blood-based MS screening depends on several factors, including:

• Validation in diverse populations: Ongoing studies in the U.S., Europe, and Asia aim to confirm the biomarkers’ accuracy across different genetic backgrounds.
• Regulatory approval: The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) would need to evaluate the test’s sensitivity and specificity before it could be marketed.
• Integration into clinical guidelines: Professional bodies like the American Committee for Treatment and Research in MS (ACTRIMS) would need to endorse its use.
• Cost and scalability: Manufacturers would need to develop an affordable, high-volume test that could be deployed globally.

Based on current progress, preliminary screening programs could emerge within 5–10 years, initially in high-resource settings. The first commercial blood test for MS risk may follow shortly after, though widespread adoption could take longer.

In the meantime, researchers are exploring additional non-invasive biomarkers, including:

• Analysis of metabolites in urine linked to MS risk.
• Advanced AI-driven imaging to detect early brain changes.
• Genetic screening for high-risk individuals.

Key Questions About Early MS Detection

1. How accurate are these blood biomarkers?

Current studies report sensitivity rates of 70–85% (correctly identifying those who will develop MS) and specificity rates of 60–75% (avoiding false positives). However, these figures vary by study and population, and larger trials are needed for confirmation.

2. Could this test replace MRI and lumbar puncture?

No—at least not initially. Blood biomarkers are likely to serve as a first-line screening tool, followed by confirmatory tests like MRI or spinal fluid analysis. “Think of it like a cholesterol test,” explained Professor Coles. “It flags who needs further evaluation, not who has the disease.”

3. Who would benefit most from early screening?

High-priority groups include:

• First-degree relatives of MS patients (parents, siblings, children).
• Individuals with the HLA-DRB1*15:01 gene variant.
• People with clinically isolated syndrome (CIS), a first episode of MS-like symptoms.
• Those living in high-prevalence regions (e.g., Northern Europe, Canada, Australia).

4. What are the risks of early diagnosis?

Potential downsides include:

• Anxiety and stress from a positive result before symptoms appear.
• Overdiagnosis in individuals who may never develop MS.
• Limited treatment options for asymptomatic individuals.

Ethical guidelines are being developed to address these concerns, including counseling protocols for at-risk individuals.